Catheter Precision (NYSE American: VTAK) sells $2,821,000 in Series C-4 preferred stock
Rhea-AI Filing Summary
Catheter Precision, Inc. completed a private financing on July 30, 2026, issuing 2,821 shares of Series C-4 Convertible Preferred Stock, par value $0.0001 and stated value $1,000 per share, for aggregate gross proceeds of $2,821,000.00. The securities were issued to investors exercising an Additional Investment Right under a March 9, 2026 Securities Purchase Agreement.
The Series C-4 terms are set out in a Certificate of Designation filed July 27, 2026 in Delaware. Dawson James Securities, Inc. acted as placement agent and received customary fees and expenses. The company plans to use net proceeds for working capital, general corporate purposes and to redeem all outstanding Series B Convertible Preferred Stock. The Series C-4 Preferred Stock ranks senior to common stock for dividends and liquidation rights, and any conversion into common stock will dilute existing common shareholders. The issuance relied on exemptions under Section 4(a)(2) and Rule 506(b) of Regulation D, with sales only to accredited investors and subject to transfer restrictions.
Positive
- None.
Negative
- None.
8-K Event Classification
4 items: 3.02, 3.03, 5.03, 9.01
4 items
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 3.03
Material Modification to Rights of Security Holders
Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.03
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Series C-4 Preferred shares issued: 2,821 shares
Stated value per Series C-4 share: $1,000 per share
Aggregate gross proceeds: $2,821,000.00
+3 more
6 metrics
Series C-4 Preferred shares issued
2,821 shares
Aggregate number of Series C-4 Convertible Preferred Stock shares issued at the Series C-4 Closing on July 30, 2026
Stated value per Series C-4 share
$1,000 per share
Stated value of each share of Series C-4 Convertible Preferred Stock
Aggregate gross proceeds
$2,821,000.00
Total gross proceeds from the sale of Series C-4 Convertible Preferred Stock
Par value per share
$0.0001 per share
Par value of the company’s Common Stock and stated for the Series C-4 Preferred Stock
Series C-4 Closing date
July 30, 2026
Date on which the company consummated the Series C-4 Closing
Certificate filing date
July 27, 2026
Date the Series C-4 Certificate of Designation was filed with the Delaware Secretary of State
Key Terms
Series C-4 Convertible Preferred Stock, Certificate of Designation, Additional Investment Right, Regulation D, +1 more
5 terms
Series C-4 Convertible Preferred Stock financial
"sale and issuance of an aggregate of 2,821 shares of the Company’s Series C-4 Convertible Preferred Stock"
Certificate of Designation regulatory
"The terms of the Series C-4 Preferred Stock are set forth in the Certificate of Designation of Preferences"
A certificate of designation is a formal document that spells out the specific rights and rules attached to a particular class or series of stock, usually preferred shares. Think of it as a rulebook or menu that lists dividend terms, liquidation priority, conversion or redemption rights and any special voting protections; investors use it to judge how much income, control or downside protection those shares will provide compared with other securities.
Additional Investment Right financial
"pursuant to the exercise by certain investors of their Additional Investment Right under Section 1(e)"
Regulation D regulatory
"in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D"
Regulation D is a set of rules that govern how companies can raise money from investors without going through the full process required for public stock offerings. It provides simplified options for private placements, making it easier for companies to seek investments from a smaller group of investors. For investors, it offers opportunities to invest in private companies, often with fewer restrictions, but also with different levels of risk and disclosure.
accredited investor regulatory
"Each Participating Buyer is an “accredited investor” as defined in Rule 501 of Regulation D"
An accredited investor is an individual or entity that meets certain financial criteria, such as having a high income or significant net worth, allowing them to invest in private or less regulated investment opportunities. This status matters because it grants access to investments that are often riskier or less available to the general public, reflecting a higher level of financial knowledge or resources.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What financing transaction did Catheter Precision (VTAK) complete on July 30, 2026?
Catheter Precision completed a private offering of 2,821 shares of Series C-4 Convertible Preferred Stock for $2,821,000.00 in gross proceeds. The issuance followed investors’ exercise of an Additional Investment Right under a March 9, 2026 Securities Purchase Agreement.
How will Catheter Precision (VTAK) use the proceeds from the Series C-4 Preferred Stock offering?
The company plans to use net proceeds from the $2,821,000.00 Series C-4 offering for working capital, general corporate purposes, and to redeem all issued and outstanding Series B Convertible Preferred Stock, reshaping its preferred equity capital structure.
What are the key terms of Catheter Precision’s (VTAK) Series C-4 Convertible Preferred Stock?
Each Series C-4 share has a par value of $0.0001 and a stated value of $1,000 per share. The Series C-4 Preferred Stock ranks senior to common stock for dividends and liquidation and is convertible into common stock, causing dilution upon conversion.
Under what securities law exemptions was Catheter Precision (VTAK)'s Series C-4 offering conducted?
The Series C-4 Preferred Stock was issued relying on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. All Participating Buyers were accredited investors, with no general solicitation and customary transfer restrictions and restrictive legends.
What role did Dawson James Securities play in Catheter Precision (VTAK)'s Series C-4 financing?
Dawson James Securities, Inc. acted as placement agent for the Series C-4 Closing. The company paid Dawson James customary placement agent fees and expenses, consistent with disclosures previously made in a March 9, 2026 report.